medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Clinical manifestations of patients with Coronavirus Disease 2019 (COVID-19) attending at hospitals in Bangladesh

Md. Shahed Morshed[1], Abdullah Al Mosabbir[2], Prodipta Chowdhury[3], Sheikh Mohammad. Ashadullah[4] and Mohammad Sorowar Hossain[2,5*]

[1]Kurmitola general hospital, Dhaka, Bangladesh

[2]Department of Emerging and Neglected Diseases, Biomedical Research Foundation, Dhaka, Bangladesh

[3]Keshabpur upazilla health complex, Jessore, Bangladesh

[4]Shailkupa upazilla health complex, Jhenaidah, Bangladesh

[5]School of Environment and Life Sciences, Independent University, Bangladesh (IUB), Dhaka, Bangladesh

Running Title: Clinical manifestations of COVID-19 patients in Bangladesh

Corresponding author

Mohammad Sorowar Hossain, Biomedical Research Foundation, Dhaka, Bangladesh

E-mail:sorowar.hossain@brfbd.org

Key words: COVID-19, Clinical manifestation, Pandemic, Bangladesh, Dhaka

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Abstract

Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension being the most common (34%), followed by diabetes mellitus (21.4%) and ischemic heart disease (9.7%). Fever (78.6%), weakness (68%) and cough (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache (32%) and body ache (32%). The median time from onset of symptom to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

Introduction

The world has been experiencing one of the most serious public health crises in the history of humankind. The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of 28 July 2020, over 16

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

million individuals have been infected with over 650,000 deaths worldwide[1]. SARS-COV-2 infection predominantly results in an acute respiratory illness. In addition, it can cause a myriad of extrapulmonary symptoms. The clinical spectrum ranges from asymptomatic or mildly symptomatic flu-like illness to potentially life-threatening critical conditions[2]. Recent studies suggest that the clinical spectrum of COVID-19 can vary among different ethnicities and geographical locations across the world[3].

Owing to a population of over 160 million, inadequate healthcare system, and poor personal hygiene among the general population, Bangladesh is considered one of the high-risk countries for coronavirus spread. The first official case of COVID-19 was reported on 8 March 2020, and the epidemic still appears to be in a growing phase. As of 30 July 2020, a total of 234,889 cases and 3083 deaths have been reported in Bangladesh[1]. However, the information on clinical manifestations from Bangladesh is scarce in the literature. Therefore, this study aimed to document the clinical spectrum of COVID-19 patients attending fever clinics in Bangladesh.

Methods

This was a cross-sectional study conducted among RT-PCR confirmed COVID-19 patients attending the fever clinic of a dedicated COVID-19 Hospital (Kurmitola general hospital) in Dhaka city of Bangladesh and two Upazila health complexes from different districts (Jessore and Jhenaidah) from 5 July to 18 July 2020. Diagnosis of SARS-COV-2 infection and assessment of severity were done based on the WHO interim guidance[4]. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. Socio-demographic and clinical data were evaluated and collected by experienced clinicians using a pretested case

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

record form. Verbal consent was taken from all participants. The institutional review board of Biomedical Research Foundation, Bangladesh approved the study protocol (Ref. no: BRF/ERB/2020/003).

Data were analysed by SPSS Statistics software 22.0 (Armonk, NY: IBM Corp). Data were expressed in number (percentages, %) and median (interquartile range, IQR) as appropriate. We used Pearson's chi square test, Fisher's exact test and Kruskal Wallis test to compare differences between mild, moderate and severe patients where appropriate. Logistic regression was used to study associations. P <0.5 was set as statistically significant.

Results

A total of 103 laboratory-confirmed COVID-19 patients were enrolled. About 75% (77) of cases presented with mild symptoms, followed by nearly 15% severe and 10% moderate cases. Overall, the median age of the participants was 37 years (IQR: 31-53); more than 80% of these patients were under 60 years (Table 1). Most of the patients were male (71.8%). More than half of the patients (52.4%) had at least one co-morbidity, including hypertension in 35 (34%), diabetes mellitus in 22 (21.4%) and ischaemic heart disease in 10 (9.7%) patients. Notably, around 80% of moderate and severe cases had comorbidity. The median time from onset of symptom to attending fever clinic was 7 days (IQR 4-10).

Overall, the most common symptoms reported were fever (78.6%), weakness (68%) and cough (44.7%) followed by loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache (32%) and body ache (32%). Less common symptoms included sore throat (28.2%), diarrhoea (22.3%) and chest pain (14.6%). Fever was the most prevalent symptom in all groups of patients. Interestingly, 80% of moderate

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

patients experienced difficulty in breathing compared to 62.5% severe patients (Table 2). More than half of the severe cases had tachycardia (56.3%) and tachypnoea (56.3%) at presentation; their median oxygen saturation was 87.5% (IQR 77.25-89.0).

Discussion

This study aimed to determine the clinical characteristics of RT-PCR confirmed noncritical patients with COVID-19 attending fever clinics of government hospitals in Bangladesh.

The most prevalent symptoms of non-critical COVID-19 patients in Bangladesh consist of fever (78.6%), fatigue (68%) and cough (44.7%). Similarly, in a meta-analysis from China, most prevalent symptoms were fever (80.4%), cough (63.1%) and fatigue (46%)[5]. However, studies from China included both critical and non-critical patients. In contrast, one study from Europe on mild to moderate patients reported that headache (70.3%), loss of smell (70.2%), nasal obstruction (67.8%) were the most common symptoms; fever was reported by only 45.4% of patients. Interestingly, 39% of mild cases, 40% of moderate cases and 12.5% of severe cases reported the altered sensation of taste or smell in this study. While olfactory and gustatory dysfunctions were prevalent symptoms in European patients, they were only rarely reported in Chinese patients[6,7].

In this study, about 15% of cases were presented with severe symptoms. This is consistent with a summary report of 72,314 cases from China[8]. As expected, most of the severe patients (81.3%) had co-morbidity. Age >60 years, patients with diabetes mellitus, ischemic heart disease and chronic kidney disease had significantly higher odds of developing severe disease at presentation (Suppl. Table 1).

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Our study has some limitations. First, the sample size of this study was small. Second, we could not include critical patients due to the requirement of emergency management. Therefore, our findings could not be generalized in the context of Bangladesh.

Our study reports the presenting symptoms of SARS-COV-2 infections among the Bangladeshi population. Although there are certain similarities in the range of symptoms with the Chinese population, where the pandemic originated, there are some unique findings like the high prevalence of olfactory and gustatory dysfunctions. This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

Conflict of interest

None of the authors has any conflict of interest to declare

Author contribution

MSM. MSH and AAM designed the study, gave professional guidance and wrote the manuscript. MSM, PC and SMA collected and analysed data.

Acknowledgement

We are grateful to Brigadier General Jamil Ahmad, director, Kurmitola General Hospital (KGH); Dr. Tania Easmin, medical officer, KGH; Dr. Md. Rashed Al Mamun, upazilla health and family planning officer (UHFPO), Shailkupa, Jhenaidah and Dr. Md. Alamgir, UHFPO, Keshabpur, Jessore for their generous support in data collection.

Funding

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Not applicable

References

1. World Health Organization. Coronavirus disease (COVID-19) situation report-190, 28 July, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200728-covid-19-sitrep-190.pdf?sfvrsn=fec17314_2. Accessed July 29, 2020
2. Zhai P, Ding Y, Wu X, Long J, Zhong Y and Li Y. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents*. 2020;55(5):105955. doi:10.1016/j.ijantimicag.2020.105955
3. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *E Clin Med*. 2020:100404. https://doi.org/10.1016/j.eclinm.2020.100404
4. World Health Organization, clinical management of COVID-19, interim guidance, 27 May 2020. https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf. Accessed August 2, 2020.
5. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. *J Med Virol*. 2020. https://doi.org/10.1002/jmv.25884
6. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med*. 2020. https://doi.org/10.1111/joim.13089
7. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020;277(8):2251-2261. doi:10.1007/s00405-020-05965-1

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

8. Wu Z and McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72□314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. *JAMA*. 2020;10. doi:10.1001/jama.2020.2648

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

List of Tables

Table 1. Characteristics of patients with COVID-19 (N= 103)

Variables	Total	Severity of patients with COVID-19			p
		Mild	Moderate	Severe	
	n (%)				
Patients' number	103 (100)	77 (74.76)	10 (9.71)	16 (15.53)	
Age (years), median (IQR)	37.0 (31.0, 53.0)	35.0 (29.0, 45.0)	52.5 (38.0, 63.25)	62.5 (42.5, 65.0)	**<0.001***
Age group					
≤60 years	84 (81.6)	70 (90.9)	7 (70.0)	7 (43.8)	**<0.001**
>60 years	19 (18.4)	7 (9.1)	3 (30.0)	9 (56.3)	
Gender					
Male	74 (71.8)	55 (71.4)	9 (90.0)	10 (62.5)	0.38
Female	29 (28.2)	22 (28.6)	1 (10.0)	6 (37.5)	
Area of residence					
Urban	69 (67)	51 (66.2)	6 (60.0)	12 (75.0)	0.73
Rural	34 (33.0)	26 (33.8)	4 (40.0)	4 (25.0)	
Smoking habit					
Smokers	32 (31.1)	25 (32.5)	3 (30.0)	4 (25.0)	0.94
Nonsmokers	71 (68.9)	52 (67.5)	7 (70.0)	12 (75.0)	
Comorbidities					
At least one comorbidity	54 (52.4)	33 (42.9)	8 (80.0)	13 (81.3)	**0.003**
Hypertension	35 (34.0)	22 (28.6)	4 (40.0)	9 (56.3)	0.09
Diabetes mellitus	22 (21.4)	10 (13.0)	4 (40.0)	8 (50.0)	**0.002**
Ischemic heart disease	10 (9.7)	4 (5.2)	2 (20.0)	4 (25.0)	**0.02**
Chronic kidney disease	8 (7.8)	3 (3.9)	1 (10.0)	4 (25.0)	**0.02**
Bronchial asthma	6 (5.8)	5 (6.5)	0 (0.0)	1 (6.3)	1.00
Chronic obstructive pulmonary disease	3 (2.9)	1 (1.3)	1 (10.0)	1 (6.3)	0.16
**Others	16 (15.5)	11 (14.3)	1 (10.0)	4 (25.0)	0.53

Within parentheses are percentages over column total of respective variable
Pearson's chi square test/ Fisher's exact test was done as appropriate *Kruskal Wallis test was done

**** Other comorbidities:Cerebrovascular disease 3 (2.9%), dyslipidemia 3 (2.9%), acute kidney injury 2 (1.9%), chronic liver disease 2 (1.9%), malignancy 1 (1.0%), Graves' thyrotoxicosis 1 (1.0%), nonalcoholic fatty liver disease 1 (1.0%), benign enlargement of prostate 1 (1.0%), allergic rhinitis 1 (1.0%), schizophrenia 1 (1.0%)

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Table 2. Clinical features of patients with COVID-19 at presentations (N= 103)

Variables	Total	Severity of COVID-19			p
		Mild	Moderate	Severe	
	n (%)				
Onset of symptom to consultation (days), median (IQR)	7.0 (4.0, 10.0)	7.0 (3.0, 10.0)	10.0 (6.75, 12.0)	9.5 (6.25, 10.0)	0.09*
Symptoms					
Fever	81 (78.6)	57 (74.0)	10 (100.0)	14 (87.5)	0.13
Weakness/ fatigue	70 (68.0)	52 (67.5)	6 (60.0)	12 (75.0)	0.73
Cough	46 (44.7)	34 (44.2)	5 (50.0)	7 (43.8)	0.95
Loss of appetite	39 (37.9)	26 (33.8)	7 (70.0)	6 (37.5)	0.10
Difficult breathing	39 (37.9)	21 (27.3)	8 (80.0)	10 (62.5)	**<0.001**
Altered smell/ taste	36 (35.0)	30 (39.0)	4 (40.0)	2 (12.5)	0.10
Headache	33 (32.0)	25 (32.5)	3 (30.0)	5 (31.3)	1.00
Bodyache	33 (32.0)	23 (29.9)	5 (50.0)	5 (31.3)	0.43
Sore throat	29 (28.2)	27 (35.1)	0 (0.0)	2 (12.5)	**0.02**
Diarrhea	23 (22.3)	18 (23.4)	1 (10.0)	4 (25.0)	0.73
Chest pain	15 (14.6)	13 (16.9)	2 (20.0)	0 (0.0)	0.14
Runny nose	12 (11.7)	9 (11.7)	1 (10.0)	2 (12.5)	1.00
Chill	11 (10.7)	8 (10.4)	0 (0.0)	3 (18.8)	0.35
Others	23 (22.3)	17 (22.1)	1 (10.0)	5 (31.3)	0.43
Signs at presentation					
Tachycardia (pulse>100 beats/ minute)	37 (35.9)	26 (33.8)	2 (20.0)	9 (56.3)	0.13
Fever (T >38°C)	16 (15.5)	12 (15.6)	1 (10.0)	3 (18.8)	0.90
Tachypnea (respiratory rate >24 breaths/ minute)	11 (10.7)	0 (0.0)	2 (20.0)	9 (56.3)	**<0.001**
Systolic blood pressure (mm-Hg), median (IQR)	120 (110, 136)	120 (110, 130)	125 (113.5, 140)	138 (120, 148.8)	**0.02***
Oxygen saturation (%), median (IQR)	96.0 (93.0, 98.0)	97.0 (95.0, 98.0)	93.0 (91.75, 98.0)	87.5 (77.25, 89.0)	**<0.001***

Within parentheses are percentages over column total of respective variable, Pearson's chi square test/ Fisher's exact test was done as appropriate *Kruskal Wallis test was done

Other symptoms: Vomiting 8 (7.8%), abdominal pain 6 (5.8%), dizziness 5 (4.9%), red eye 4 (3.9%)

medRxiv preprint doi: https://doi.org/10.1101/2020.07.30.20165100; this version posted August 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Supplementary materials

Suppl. Table 1. Binary logistic regression analysis to predict the severe disease at presentation

Covariates	OR (95% CI)	p
Age >60 years	9.90 (3.02, 32.45)	**<0.001**
Diabetes mellitus	5.21 (1.68, 16.22)	**0.004**
Ischemic heart disease	4.50 (1.11, 18.30)	**0.04**
Chronic kidney disease	6.92 (1.52, 31.38)	**0.01**

CI, confidence interval; OR, odds ratio

Reference category is nonsevere illness (mild and moderate disease)